AGC and RoosterBio partner for cell and exosome therapy manufacturing
Pharmaceutical Technology
AUGUST 17, 2022
Other capabilities include upstream processing in 2D flask and 3D bioreactor systems, downstream purification for attaining preferred purity and potency, as well as complete analytical characterisation of the resultant cell or exosome therapy that is formulated. . Topic sponsors are not involved in the creation of editorial content.
Let's personalize your content